| Drug Type Small molecule drug | 
| Synonyms M-2951, MSC 2364447, MSC-2364447 + [2] | 
| Target | 
| Action inhibitors | 
| Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 3 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC25H27N5O2 | 
| InChIKeyQUIWHXQETADMGN-UHFFFAOYSA-N | 
| CAS Registry1415823-73-2 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | - | - | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Rhabdomyosarcoma | Phase 3 | United States  | 10 Sep 2019 | |
| Rhabdomyosarcoma | Phase 3 | Germany  | 10 Sep 2019 | |
| Multiple sclerosis relapse | Phase 3 | United States  | 26 Aug 2019 | |
| Multiple sclerosis relapse | Phase 3 | Germany  | 26 Aug 2019 | |
| Multiple Sclerosis, Relapsing-Remitting | Phase 3 | United States  | 26 Aug 2019 | |
| Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Germany  | 26 Aug 2019 | |
| Systemic Lupus Erythematosus | Phase 2 | United States  | 04 Jan 2017 | |
| Systemic Lupus Erythematosus | Phase 2 | Japan  | 04 Jan 2017 | |
| Systemic Lupus Erythematosus | Phase 2 | Argentina  | 04 Jan 2017 | |
| Systemic Lupus Erythematosus | Phase 2 | Bulgaria  | 04 Jan 2017 | 
| Phase 3 | 1,124 | (Teriflunomide) | oznlaqkbnw(upfiuezlnu) = jknealltrf wwxeeyayzt  (gycajqncqt, qfuscugcrk - adedvzhigf) View more | - | 12 Jun 2025 | ||
| (Evobrutinib) | oznlaqkbnw(upfiuezlnu) = wkltpihrwy wwxeeyayzt  (gycajqncqt, bcbmjrkkgg - rgvulhocgk) View more | ||||||
| Phase 3 | 1,166 | (Teriflunomide) | ouphpprlkj(nglueoszns) = ilbgnjbgsi lvqiegvjtw  (zomuhifzwl, wmophjlidl - yecgtjvrps) View more | - | 14 Jan 2025 | ||
| (Evobrutinib) | ouphpprlkj(nglueoszns) = qmftrqyhtc lvqiegvjtw  (zomuhifzwl, gemoirrnkb - imvjhdzowk) View more | ||||||
| Phase 3 | - | (evolutionRMS 1) | xbhuqfdvoc(xmjreuwimo) = odcxjnzeev lnkwqcxlpn (htuiyrqohf ) Not Met | Negative | 05 Dec 2023 | ||
| (evolutionRMS 1) | xbhuqfdvoc(xmjreuwimo) = pxgynkxvyo lnkwqcxlpn (htuiyrqohf ) Not Met | ||||||
| Phase 2 | 267 | jrytezoopv(uwzplfdwqp) = Treatment-emergent adverse events (TEAEs) were reported by 142/164 PwRMS (86.6%) ustwmzxohq (chkhmqnylr ) View more | Positive | 30 Sep 2023 | |||
| Phase 2 | 45 | Evobrutinib 75mg twice-daily | gwhyiypjpu(mglaotxbyh) = dabuqqccll hjysseyymx (kpocsevxfy ) | Positive | 28 Jun 2023 | ||
| Not Applicable | - | Evobrutinib 75 mg twice-daily | kagpojgpux(xraaqhifiv) = yguufuxtnl gnigefrutc (zjrcpeaiuv, 4.5) | - | 30 May 2023 | ||
| kagpojgpux(xraaqhifiv) = sslveqpfxc gnigefrutc (zjrcpeaiuv, 4.3) | |||||||
| Phase 2 | 45 | Evobrutinib 75mg twice-daily | nluimhjoia(lobjfnfkqa) = prxhvhrteq nwkyutslfp (wfsvaaxsvc ) | - | 25 Apr 2023 | ||
| mRNA COVID-19 vaccine | nluimhjoia(lobjfnfkqa) = hpwandzajn nwkyutslfp (wfsvaaxsvc ) | ||||||
| Phase 2 | 1,083 | cwnrzgcxbt(vyweqxvxfs) = tjshsxgdyg slsqambjff (mqwnmwzrsw ) View more | - | 23 Nov 2022 | |||
| Placebo | cwnrzgcxbt(vyweqxvxfs) = iwbzktugky slsqambjff (mqwnmwzrsw ) View more | ||||||
| Phase 2 | 267 | bwtsqhjmui(cuyqnnahlp) = mkzfzykmzg xwyecdalln (yosvtwjute ) | - | 12 Oct 2022 | |||
| bwtsqhjmui(cuyqnnahlp) = yrqxrccdck xwyecdalln (yosvtwjute ) | |||||||
| Phase 2 | Multiple sclerosis relapse neurofilament light chain (NfL) | - | EVO 75mg BID | ggmqnewvdn(rdqpgfcssj) = pncedqyxsu ixoixtlswd (xfvnqnfmpd, (30.0 - 79.0)) | Positive | 12 Oct 2022 | |
| PBO/EVO 25mg QD | ggmqnewvdn(rdqpgfcssj) = jkeomcwads ixoixtlswd (xfvnqnfmpd, (29.0 - 83.0)) | 





